Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer
Vanessa F. Merino(University of Maryland, Baltimore), Saraswati Sukumar(Johns Hopkins University), David L. Huso(Johns Hopkins University), Xian Zhou(The University of Texas Health Science Center at Houston), Peter Ordentlich(Kala Pharmaceuticals (United States)), Soonweng Cho(Kennedy Krieger Institute), Preethi Korangath(Johns Hopkins University), Kideok Jin(Johns Hopkins University), Vered Stearns(Johns Hopkins University), Yolanda M.N. Foster(Johns Hopkins University), Christina Adams(Johns Hopkins University), Duojia Pan(Howard Hughes Medical Institute), Qian Chen(Johns Hopkins University), Zhe Zhang(Johns Hopkins University), Liangfeng Han(Johns Hopkins University), Helen Sadik(Cornell University), Nguyen Nguyen(Johns Hopkins University), Roisín M. Connolly(Johns Hopkins University), Angela Brodie(University of Maryland, Baltimore), Syed Z. Ali(Johns Hopkins Hospital)
Cited by 48
Related Papers
The Genomic Landscapes of Human Breast and Colorectal Cancers
|Science|2007|2.8k
Molecular Definition of Breast Tumor Heterogeneity
|Cancer Cell|2007|1.4k
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
|JNCI Journal of the National Cancer Institute|2005|947
Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
|JNCI Journal of the National Cancer Institute|2003|850
The Merlin/NF2 Tumor Suppressor Functions through the YAP Oncoprotein to Regulate Tissue Homeostasis in Mammals
|Developmental Cell|2010|827